PCMC
ITRM

Planning Capital Management Corporation’s Iterum Therapeutics ITRM Stock Holding History

Planning Capital Management Corporation’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$44 Hold
40
– – ﹤0.01% 748
2024
Q2 		$46 Buy
+40
New +$58 ﹤0.01% 689

Other funds holding ITRM

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
AF
Apollon Financial Mount Pleasant, South Carolina $848M AUM 27.31% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Planning Capital Management Corporation's ITRM Position: Q3 2024 in Review

Planning Capital Management Corporation held its Iterum Therapeutics (ITRM) position steady in Q3 2024 at 40 shares worth $44. The position accounts for ﹤0.01% of the portfolio, ranked #748.

Planning Capital Management Corporation first reported a position in ITRM in Q2 2024 and has held it in 2 quarters since. The position peaked at $46 in Q2 2024. 18 funds tracked by Wall St. Rank hold ITRM as of Q3 2024.

  • Planning Capital Management Corporation held 40 shares of Iterum Therapeutics worth $44 as of Q3 2024.
  • Planning Capital Management Corporation left its Iterum Therapeutics share count unchanged in Q3 2024.
  • Iterum Therapeutics made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #748 holding.
  • Planning Capital Management Corporation first reported a position in Iterum Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • Planning Capital Management Corporation's Iterum Therapeutics position peaked at $46 in Q2 2024.
  • 18 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.